ABIVAX Société Anonyme (ABVX)

NGM – Real Time Price. Currency in USD

121.39

-0.74 (-0.61%)

At close: May 12, 2026, 4:00 PM EDT

121.03

-0.36 (-0.30%)

Pre-market: May 13, 2026, 8:57 AM EDT

05.05.2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

22.04.2026

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that nine scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the 2026 Digestive Disease Week (DDW) taking place May 2-5, 2026 in Chicago, IL. These presentations will highlight data from the Phase 3 ABTECT program, including efficacy, safety, and patient-reported outcomes, along with preclinical anti-fibrotic activity in two preclinical fibrosis models.

20.04.2026

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

07.04.2026

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.

01.04.2026

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026. The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

01.04.2026

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.

26.03.2026

2 Healthcare Stocks That Could Soar Over the Next 5 Years

These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.

Videos

No Data

There is no data to display

Press releases

05.05.2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

20.04.2026

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

01.04.2026

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

21.02.2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

ABIVAX Société Anonyme (ABVX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ABIVAX Société Anonyme (ABVX)

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Videos

No Data

Press releases

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Videos

No Data

Press releases

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Search stocks

ABIVAX Société Anonyme (ABVX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ABIVAX Société Anonyme (ABVX)

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Videos

No Data

Press releases

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Videos

No Data

Press releases

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026